Certara, Inc. (NASDAQ:CERT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Certara, Inc. (NASDAQ:CERT) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $15.67.

A number of research analysts have issued reports on CERT shares. Robert W. Baird boosted their price objective on shares of Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research report on Friday, April 11th. JMP Securities restated a “market perform” rating on shares of Certara in a research note on Tuesday, May 6th. William Blair restated a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. KeyCorp increased their price objective on shares of Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th. Finally, Stephens reissued an “overweight” rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th.

Institutional Investors Weigh In On Certara

Several hedge funds have recently bought and sold shares of the stock. ArrowMark Colorado Holdings LLC raised its stake in shares of Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after buying an additional 3,861,674 shares during the period. Ameriprise Financial Inc. raised its stake in Certara by 864.0% in the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company’s stock valued at $40,253,000 after purchasing an additional 3,387,590 shares during the last quarter. Mackenzie Financial Corp acquired a new position in Certara in the 4th quarter valued at $17,852,000. Brown Brothers Harriman & Co. raised its stake in Certara by 63.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company’s stock valued at $40,668,000 after purchasing an additional 1,487,998 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Certara by 169.0% in the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company’s stock valued at $21,248,000 after purchasing an additional 1,253,385 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Stock Up 1.6%

Shares of NASDAQ CERT opened at $12.18 on Friday. The company has a market capitalization of $1.98 billion, a P/E ratio of -60.90, a price-to-earnings-growth ratio of 9.29 and a beta of 1.44. Certara has a 52-week low of $8.64 and a 52-week high of $16.93. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company’s 50 day moving average price is $12.15 and its 200-day moving average price is $11.87.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. During the same quarter in the previous year, the company earned $0.10 EPS. Certara’s quarterly revenue was up 9.7% compared to the same quarter last year. Equities analysts forecast that Certara will post 0.28 earnings per share for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.